Morgan Stanley maintains Ryan Specialty Holdings at Overweight, raises price target to $55 from $50

Morgan Stanley kept Ryan Specialty Holdings at Overweight, raising its price target to $55 from $50, implying a 17.3% upside from the last close of $46.89. Recent analyst price targets for the company range from $46 to $52.

Original reporting
Published Nov 16, 2026, 3:25 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 16, 2026, 3:33 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Morgan Stanley maintains Ryan Specialty Holdings at Overweight, raises price target to $55 from $50 — source image
Decision brief

The 30-second read

Med
01

Why it matters

The analyst upgrade signals confidence in the company's earnings outlook and may prompt short-term buying.

02

Market read

A fresh price target increase can influence investor sentiment and short-term price action for RYI.

03

What to watch

Potential exposure to underwriting cycles and macro insurance loss trends.

Relevance 5/10Novelty 5/10Timing: today

Background

Ryan Specialty Holdings is a specialty insurance provider listed on NYSE under ticker RYI.

Market effects

May lift other specialty insurance peers as the sector receives a positive analyst note.

Limited to U.S. markets where the stock trades.

Low

Counterpoint

The target raise could be premature if underlying earnings growth does not support the higher valuation.

Key entities

  • Morgan Stanley

    Equity research firm that issued the upgraded price target.

  • Ryan Specialty Holdings

    Specialty insurance firm receiving the upgraded target.

Related articles

$RYANMed

Ryan Specialty Holdings Inc (RYAN) (Q3 2026) Earnings Call Highlights: Revenue Growth

Ryan Specialty Holdings (RYAN) reported Q3 2026 revenue growth slowing to 4% from 15% YoY, with adjusted EBITDAC margin down 30 bps to 30.9%. The company cited market challenges, including property pricing declines and increased competition. Management expects continued pressure in Q4 2026 and 2027, with modest margin expansion anticipated. They also discussed growth opportunities in reinsurance and AI-related risks, and potential M&A activity in 2027.

Med

Ryan Specialty grows revenue as property softening squeezes E&S returns

Ryan Specialty reported a 4.7% revenue increase to $790M in Q3 2026, driven by casualty lines, while property revenue declined. Underwriting management grew 5.4%, expanding its share of total revenue. Expenses rose 9.9%, outpacing revenue growth. The company maintained its full-year guidance for mid-single-digit organic revenue growth and reported a 3.8% increase in adjusted EBITDAC to $244.4M.